BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

...region with a peptide that is cleaved by proteases in the tumor microenvironment. The company’s CX-072...
BioCentury | Feb 26, 2019
Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

...Probody CX-188. CytomX's lead program, CX-072, is a PD-L1 Probody immunotherapy in the Phase I/II PROCLAIM-CX-072...
...At the R&D day, the company reported a low incidence of treatment-related adverse events with CX-072...
...combo led to four confirmed responses among 19 evaluable patients. Additional data from PROCLAIM-CX-2009 and PROCLAIM-CX-072...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

...Johnson, Staff Writer Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris (Other) Besponsa, inotuzumab ozogamicin (CMC-544, PF-5208773) CX-072 Kadcyla...
BioCentury | Jul 20, 2018
Financial News

CytomX raises $125M follow-on

...lymphomas. CX-072 is a Probody targeting PD-L1. CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Jennie Walters CX-072 CytomX...
BioCentury | Jul 13, 2018
Financial News

Follow-on roundup: Myovant, CytomX, Spero

...PROCLAIM-CX-072 trial of lead candidate CX-072 to treat advanced or recurrent solid tumors or lymphomas. CX-072...
...antibiotic marketed in Japan by Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) for pediatric infections. Jennie Walters CX-072 Orapenem...
BioCentury | Jun 8, 2018
Clinical News

CytomX reports updated Phase I data for CX-072 in solid tumors

...CytomX Therapeutics Inc. (NASDAQ:CTMX) reported updated data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as...
...of Clinical Oncology meeting in Chicago. In 20 evaluable patients with advanced solid tumors, IV CX-072...
...CytomX said CX-072 as monotherapy led to two partial responses in 17 evaluable patients, and CX-072...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...will present safety and efficacy data for CX-072 in patients with solid tumors or lymphoma. CX-072...
...2 PR and 3 SD in 20 pancreatic cancer patients 4123 CytomX Therapeutics Inc. (NASDAQ:CTMX) CX-072...
BioCentury | May 25, 2018
Clinical News

CytomX reports Phase I data for CX-072 in solid tumors

...CytomX Therapeutics Inc. (NASDAQ:CTMX) reported preliminary data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as...
...pair of abstracts ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. CX-072...
...is a Probody targeting PD-L1. In 17 evaluable patients with heavily pretreated solid tumors, IV CX-072...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...refractory aggressive B cell non-Hodgkin's lymphoma (NHL) Ph III data 1H18 CytomX Therapeutics Inc. (NASDAQ:CTMX) CX-072...
...using peptide “masks” that are cleaved by proteases specific to the tumor microenvironment. Lead candidate CX-072...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...conjugates (ADCs) and T cell-engaging bispecific antibodies by restricting their activity to tumors. Lead candidate CX-072...
Items per page:
1 - 10 of 15